-
公开(公告)号：EP3317266A1
公开(公告)日：2018-05-09
申请号：EP16738842.0
申请日：2016-06-30
申请人： Orion Corporation
IPC分类号： C07D401/14 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/14 , A61K31/4709 , A61P35/00 , A61P37/00
CPC分类号： C07D413/14 , C07D401/14 , C07D405/14 , C07D413/10 , C07D417/04 , C07D417/14
摘要： wherein Cy1, Cy2, R1, R2, and L1 have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.
-
公开(公告)号：EP2981533A1
公开(公告)日：2016-02-10
申请号：EP14722686.4
申请日：2014-04-03
申请人： Orion Corporation
发明人： RAJAGOPALAN, Srinivasan , APPUKUTTAN, Prasad , NARASINGAPURAM ARUMUGAM, Karthikeyan , UJJINAMATADA, Ravi Kotrabasaiah , GEORGE, Shyla , LINNANEN, Tero
IPC分类号： C07D401/14 , C07D471/04 , A61K31/4439 , A61P35/00
CPC分类号： C07D401/14 , C07D403/14 , C07D471/04
摘要： A compound of formula (I), wherein R
1 to R
5 , A, B, Z, Z
1 and Z
2 are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.摘要翻译： 公开了其中R 1至R 5，A，B，Z，Z 1和Z 2如权利要求中所定义的式（I）化合物或其药学上可接受的盐。 式（I）化合物具有作为FGFR抑制剂的效用，并且可用于治疗期望FGFR激酶抑制的病症，例如癌症。
-
3.发明公开SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS 审中-公开SPIRO [环丁烷-1,3'-吲哚啉] -2'-ONE衍生物作为BROMODOMAIN抑制剂
公开(公告)号：EP3310772A1
公开(公告)日：2018-04-25
申请号：EP16733625.4
申请日：2016-06-15
申请人： Orion Corporation
发明人： UJJINAMATADA, Ravi Kotrabasaiah , SAMAJDAR, Susanta , ABBINENI, Chandrasekhar , MUKHERJEE, Subhendu , LINNANEN, Tero , WOHLFAHRT, Gerd
IPC分类号： C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D417/06 , C07D451/06 , C07D453/02 , C07D209/96 , A61K31/403 , A61P35/00
CPC分类号： C07D209/96 , A61P29/00 , A61P35/00 , A61P37/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/06 , C07D451/06 , C07D453/02
摘要： in which Cy, R1, R2, R4, L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.
-
公开(公告)号：EP2766354A1
公开(公告)日：2014-08-20
申请号：EP12783247.5
申请日：2012-10-09
申请人： Orion Corporation
发明人： LINNANEN, Tero , WOHLFAHRT, Gerd , NANDURI, Srinivas , UJJINAMATADA, Ravi , RAJAGOPALAN, Srinivasan , MUKHERJEE, Subhendu
IPC分类号： C07D401/14 , C07D403/04 , C07D413/04 , A61K31/4184 , A61K31/4188 , A61P35/00 , C07D471/04
CPC分类号： A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , C07D235/20 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04
摘要： A compound of formula (I), wherein R
3 , R
4 , G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.摘要翻译： 公开了其中R 3，R 4，G，B，M和Z如权利要求中所定义的式（I）化合物及其药学上可接受的盐。 式（I）化合物具有作为FGFR抑制剂的用途，并且可用于治疗需要FGFR激酶抑制的病症，例如癌症。
-
公开(公告)号：EP2834233B1
公开(公告)日：2018-04-25
申请号：EP13719297.7
申请日：2013-03-28
申请人： ORION CORPORATION
IPC分类号： C07D405/04 , C07D409/04 , A61K31/4178 , A61P25/00 , A61P9/00
CPC分类号： C07D409/04 , A61K31/4178 , C07D233/04 , C07D405/04 , C07D405/14
摘要： Compounds of formula (I), wherein X and R1-R6, are as defined in the claims, exhibit alpha2 agonistic activity and thus are useful as alpha2 agonists, especially as alpha2A agonists. Methods of use of said compounds are also provided.
-
公开(公告)号：EP2766354B1
公开(公告)日：2016-05-18
申请号：EP12783247.5
申请日：2012-10-09
申请人： Orion Corporation
发明人： LINNANEN, Tero , WOHLFAHRT, Gerd , NANDURI, Srinivas , UJJINAMATADA, Ravi , RAJAGOPALAN, Srinivasan , MUKHERJEE, Subhendu
IPC分类号： C07D401/14 , C07D403/04 , C07D413/04 , A61K31/4184 , A61K31/4188 , A61P35/00 , C07D471/04
CPC分类号： A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , C07D235/20 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04
-
公开(公告)号：EP2981533B1
公开(公告)日：2017-12-06
申请号：EP14722686.4
申请日：2014-04-03
申请人： Orion Corporation
发明人： RAJAGOPALAN, Srinivasan , APPUKUTTAN, Prasad , NARASINGAPURAM ARUMUGAM, Karthikeyan , UJJINAMATADA, Ravi Kotrabasaiah , GEORGE, Shyla , LINNANEN, Tero
IPC分类号： C07D401/14 , C07D471/04 , A61K31/4439 , A61P35/00
CPC分类号： C07D401/14 , C07D403/14 , C07D471/04
-
公开(公告)号：EP2834233A1
公开(公告)日：2015-02-11
申请号：EP13719297.7
申请日：2013-03-28
申请人： Orion Corporation
IPC分类号： C07D405/04 , C07D409/04 , A61K31/4178 , A61P25/00 , A61P9/00
CPC分类号： C07D409/04 , A61K31/4178 , C07D233/04 , C07D405/04 , C07D405/14
摘要： Compounds of formula (I), wherein X and R1-R6, are as defined in the claims, exhibit alpha2 agonistic activity and thus are useful as alpha2 agonists, especially as alpha2A agonists. Methods of use of said compounds are also provided.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.02 秒)
